Galapagos NV (WBO:GLPG) Total Current Assets : €3,472.4 Mil (As of Mar. 2025)

View and export this data going back to 2017. Start your Free Trial

What is Galapagos NV Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Galapagos NV's total current assets for the quarter that ended in Mar. 2025 was €3,472.4 Mil.

Galapagos NV Total Current Assets Historical Data

The historical data trend for Galapagos NV's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Total Current Assets Chart

Galapagos NV Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Current Assets

Get a 7-Day Free Trial

5,369.35

4,861.85

4,236.85

3,861.59

3,339.45

Galapagos NV Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Current Assets	Get a 7-Day Free Trial															3,786.47	3,665.19	3,559.43	3,339.45	3,472.35

Galapagos NV Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Galapagos NV's Total Current Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	3117.573	+	88.09	+	51.192	+	82.595
	=	3,339.5

Galapagos NV's Total Current Assets for the quarter that ended in Mar. 2025 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	3297.302	+	83.49	+	38.516	+	53.046
	=	3,472.4

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Galapagos NV (WBO:GLPG) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Galapagos NV's Liquidation Value for the quarter that ended in Mar. 2025 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	3297.302	-	1274.052	+	0.75 * 51.148	+	0.5 * 38.516
=	2,080.9

Galapagos NV Total Current Assets Related Terms

Thank you for viewing the detailed overview of Galapagos NV's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Galapagos NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (WBO:GLPG) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

GLPGF:USA GLPG:USA GLPG:Netherlands GLPGa:UK 0JXZ:UK GXEA:Germany GXE:Germany GXEA:Germany GXE:Germany G1LP34:Brazil

Address

Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800

Website

https://www.glpg.com

Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.